Tenax Therapeutics, Inc.
TENX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.01 | 0.00 | -0.04 |
| FCF Yield | -15.67% | -108.35% | -367.86% | -50.76% |
| EV / EBITDA | 0.02 | 0.50 | -0.18 | -0.50 |
| Quality | ||||
| ROIC | -21.19% | -95.75% | -480.42% | -704.95% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.77 | 1.09 | 0.33 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -150.88% | 50.87% | -10.62% | -17.09% |
| Safety | ||||
| Net Debt / EBITDA | 5.40 | 1.21 | 0.12 | 0.16 |
| Interest Coverage | -847.57 | -343.55 | -2,487.65 | -34,487.08 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -99,960.29 | -1,444.21 | -2,879.08 |